This study is looking at a new blood test called NavDx® for women with high-grade cervical dysplasia (pre-cancerous cells) or cervical cancer caused by Human Papilloma Virus (HPV). Currently, diagnosing and monitoring these conditions often requires invasive procedures. NavDx® is designed to detect tiny fragments of HPV DNA from cancer cells in your blood, potentially offering a simpler way to screen and monitor these conditions. We want to see if the levels of this HPV DNA in your blood change before, during, and after treatment. We are looking for 100 women aged 18 and older who have been diagnosed with HPV-related high-grade cervical dysplasia or invasive cervical cancer to participate.

Study design

This is an interventional study planning to enroll 100 participants. It is not specified if it is randomized or blinded.

What's involved

You would have blood tests to measure circulating HPV DNA at the start of the study, up to 8 weeks later, and again at 8-12 weeks.

Compensation

Not stated in the trial record.

Follow-up

Circulating HPV DNA will be measured up to 8-12 weeks after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.